Published 19 September 2026 · Last reviewed 19 September 2026
Every aesthetic provider knows the scenario. The in-office treatment went exactly as planned — the patient was pleased at checkout. Weeks later, at follow-up, the result hasn't held. The culprit is rarely the procedure. More often, it's what is — or isn't — happening in the patient's home care.
Home care is where clinical outcomes are consolidated. It is also where many practices quietly lose credibility and revenue.
The compliance problem that isn't compliance
When a patient doesn't improve between visits, the default assumption is non-compliance. Sometimes that's accurate. But across years of formulation work alongside skin-health professionals, we've observed a more uncomfortable pattern: many patients are using their products as directed. The products simply aren't delivering.
Much of the mass market is optimized for sensorial appeal and shelf stability: water-based vehicles that feel elegant and evaporate quickly; actives included at marketing-relevant rather than function-relevant concentrations; formulas whose pH undermines the very actives they advertise. Retinoids that irritate without reaching their target. Vitamin C oxidized before first use.
The clinical consequence: patients apply these products twice daily, see no change, and conclude that skincare "doesn't work" — a conclusion that quietly extends to the professional who recommended it.
Delivery is a formulation variable, not a marketing term
The formulation principle can be stated in one sentence: an ingredient can only act where it reaches.
The stratum corneum is lipid-rich by design; it is more permeable to lipid-compatible vehicles than to water-based ones. This is the rationale behind transdermal delivery systems: formulating actives within lipid-compatible vehicles that respect the barrier's own logic. The practical results are threefold —
Stability: anhydrous, lipid-based formats protect oxidation-prone actives (notably vitamin C) across the product's life.
Penetration: lipid vehicles partition into the skin's lipid matrix, carrying actives beyond the surface layers.
Tolerability: gradual release from the vehicle reduces the surface irritation associated with conventional retinoid formats — the leading cause of patient discontinuation in weeks one and two.
For a practice, this is the difference between retailing products and retailing outcomes.
What outcome-oriented home care looks like
Retail what you would use yourself. If a formulation wouldn't earn a place in your own routine for 90 days, it doesn't belong on your shelf. Retail is a clinical statement.
Curate depth, not breadth. A coherent system of a small number of formulations designed to work together outperforms a wide catalog — for staff education, patient compliance, and average transaction value alike.
Set expectations with mechanisms, not adjectives. "This vitamin C supports collagen synthesis between visits" converts and retains better than "our bestseller," because patients remain loyal to what they understand.
Treat wholesale as a clinical tool. Lines with true professional margins let practices retail at sensible multiples while remaining below prestige retail pricing — sustainable for the patient, viable for the practice, and consistent with professional protocols.
The bottom line
In-office work creates the result. Home care determines whether it endures. When both operate at the same standard, retail stops being an add-on and becomes part of the treatment itself — protecting outcomes, reinforcing trust, and building a revenue stream that compounds with every satisfied patient.
Scope: this article describes formulation principles and practice considerations. It is not a claim to diagnose, treat, cure or prevent any disease, and it is not a performance claim for any product.
TTS Clinical · Trusted by skin health professionals · Where formula meets biology · www.ttsclinical.com